U.S. Biomarker Test Market Size, Share & Forecast 2026–2032

ID: MR-11688 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Biomarker Test Market
  • ✓Market Size 2024: USD 18.6 billion
  • ✓Market Size 2032: USD 38.9 billion
  • ✓CAGR: 9.8%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Payers Now Gatekeep: FDA's LDT rule was vacated in March 2025, so Medicare coverage through MolDX, administered by Palmetto GBA, now decides commercial viability. Guardant Health and Foundation Medicine treat reimbursement evidence, not FDA clearance, as their primary regulatory asset.
FINDING 02
Federal Research Funding Overrated: Commentators credit federal research funding for adoption. The sharper driver is the CMS Clinical Laboratory Fee Schedule, where PAMA-based private payer rate reporting pushes reimbursement down, squeezing mid-sized labs and accelerating consolidation toward Labcorp and Quest Diagnostics.
ANALYST RECOMMENDATION

Analyst Recommendation — Prioritize Coverage Evidence Now: Diagnostics developers must file MolDX technical assessment submissions before the end of 2026, using real-world utilization data from oncology practices. Early MolDX coverage determines which commercial payers follow, so delay forfeits the reimbursement window for next-generation sequencing panels.

Biomarker Testing in the United States: Market Overview

The U.S. biomarker test market was valued at USD 18.6 billion in 2024 and is projected to reach USD 38.9 billion by 2032, growing at a 9.8% CAGR. Oncology accounts for the largest share, with companion diagnostics and next-generation sequencing panels delivered through reference laboratories such as Labcorp and Quest Diagnostics alongside specialist firms including Foundation Medicine and Guardant Health. The structure is hybrid: private laboratories and developers lead commercial innovation, while federal bodies set the rules of entry and payment.

Government has been the dominant force in shaping demand through the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with the CDC, which set analytical quality standards for every testing laboratory. Medicare coverage determinations then set reimbursement levels that define commercial viability. The private sector has led platform development, with Illumina and Thermo Fisher Scientific supplying sequencing infrastructure and Tempus AI building data-linked testing services.

Policy-Driven Growth in U.S. Biomarker Testing

The 21st Century Cures Act of 2016 funded the Cancer Moonshot with USD 1.8 billion over seven years, channelled through the National Cancer Institute. This money built biomarker-driven trial infrastructure, so trial-linked testing flowed to commercial laboratories. Medicare National Coverage Determination 90.2, effective 2018, covers next-generation sequencing for beneficiaries with advanced cancer, which guarantees payment volume for oncology panels.

Medicare Administrative Contractor coverage through the MolDX program, operated by Palmetto GBA, issues Local Coverage Determinations for multi-biomarker panels, translating technical assessment into payer-wide reimbursement. Each determination converts a laboratory's validated test into a billable service across participating states. Together, these three mechanisms convert research spending and clinical evidence into predictable revenue, which attracts capital into test development.

Regulatory Barriers and Compliance Costs

Every laboratory performing biomarker tests on human specimens must hold a CLIA certificate from CMS, with the CDC providing technical guidance on proficiency testing. New York State adds a further barrier: the Department of Health's Clinical Laboratory Evaluation Program requires a separate permit before a laboratory can test specimens from New York patients. Permit reviews routinely extend market entry by several months and add substantial compliance cost for national laboratories.

Reimbursement compression presents the second barrier. Under the Protecting Access to Medicare Act of 2014, CMS sets Clinical Laboratory Fee Schedule rates using private payer data, and statutory reductions are capped at 15% per year. Laboratories without scale absorb these cuts, while the Federal Food, Drug, and Cosmetic Act and FDA oversight add validation burdens for companion diagnostics.

Policy-Created Opportunities in U.S. Biomarker Testing

The CMS Transitional Coverage for Emerging Technologies pathway offers coverage to designated breakthrough devices before traditional national coverage is settled. Developers holding FDA Breakthrough Device designation can access this route, which accelerates revenue for novel multi-cancer and minimal residual disease assays. Early enrollment in this pathway provides a reimbursement advantage over competitors awaiting standard determinations.

The Department of Veterans Affairs Million Veteran Program offers a large, consented genomic cohort that supports validation studies and procurement contracts with federal health systems. Laboratories that partner with VA medical centers gain access to a captive patient population with high cancer incidence. The All of Us Research Program, funded through the Cures Act, similarly creates validated datasets for pharmacogenomic and biomarker test development.

Market at a Glance

MetricValue
Market Size 2024USD 18.6 billion
Market Size 2032USD 38.9 billion
Growth Rate (CAGR)9.8%
Most Critical Decision FactorPayer coverage determination under MolDX and NCD 90.2
Largest RegionNortheast and Mid-Atlantic corridor
Competitive StructureConsolidated laboratory leaders with fragmented specialist firms

Leading Market Participants

  • Labcorp
  • Quest Diagnostics
  • Natera
  • Guardant Health
  • Foundation Medicine
  • Myriad Genetics
  • Exact Sciences
  • Illumina
  • Tempus AI
  • Caris Life Sciences

Regulatory and Policy Environment

The primary legislation is the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with CDC support, which requires CLIA certification, proficiency testing, and quality control for every laboratory. The FDA's final rule on laboratory developed tests, issued in May 2024, was vacated by the U.S. District Court for the Eastern District of Texas in March 2025 in American Clinical Laboratory Association v. FDA. Laboratory developed tests therefore remain outside FDA premarket review, and the Federal Food, Drug, and Cosmetic Act governs only FDA-cleared or approved devices.

Upcoming changes centre on the Medicare Clinical Laboratory Fee Schedule, updated annually under PAMA, with rate effects taking hold each January 1. Congressional proposals to create federal LDT oversight, including successors to the VALID Act, remain under review without enactment. Against regional peers, the U.S. framework is more permissive than the European Union's In Vitro Diagnostic Regulation (EU) 2017/746, whose transition deadlines run through 2027 and 2029 and impose full conformity assessment on laboratory tests.

Long-Term Policy Outlook for U.S. Biomarker Testing

By 2032, payer-led coverage will be the principal regulatory mechanism for biomarker testing, with MolDX determinations and NCD 90.2 shaping which panels reach patients. Expect PAMA reform to remain a central legislative issue, since reimbursement compression determines which laboratories survive consolidation. Federal LDT oversight will stay contested, so laboratories will carry the compliance burden of analytical validation regardless of FDA's formal authority.

The market will reshape around laboratories that combine scale with validated real-world evidence. Companies able to satisfy MolDX technical assessment and CLIA requirements across all states will gain share, while smaller specialist firms will need partnerships or acquisition. Policy direction therefore points toward concentration, with reimbursement evidence becoming the decisive competitive asset through the forecast period.

Frequently Asked Questions

CMS administers the Clinical Laboratory Improvement Amendments of 1988 with CDC technical support, requiring CLIA certification for every laboratory testing human specimens. States such as New York impose additional permit requirements on top of federal certification.
No, the U.S. District Court for the Eastern District of Texas vacated the rule in March 2025. Laboratory developed tests therefore remain outside FDA premarket review under current law.
NCD 90.2 establishes Medicare coverage for next-generation sequencing tests for beneficiaries with advanced cancer. It provides a national payment basis that commercial payers frequently reference.
MolDX, operated by Palmetto GBA, issues Local Coverage Determinations for molecular diagnostic tests across participating Medicare contractor jurisdictions. Its technical assessment process determines whether a biomarker panel receives payer-wide coverage.
PAMA requires CMS to set Clinical Laboratory Fee Schedule rates from private payer data, with annual reductions capped at 15%. Laboratories with limited scale face the greatest margin pressure from these statutory cuts.

Market Segmentation

By Test Type
  • Next-Generation Sequencing Panels
  • Companion Diagnostics
  • Immunohistochemistry Assays
  • Liquid Biopsy Tests
  • Pharmacogenomic Tests
By Application
  • Oncology
  • Cardiovascular Disease
  • Neurology
  • Infectious Disease
By End User
  • Reference Laboratories
  • Hospital Laboratories
  • Academic Medical Centers
  • Pharmaceutical Companies
  • Federal Health Systems

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 U.S. Biomarker Testing - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Test Type Insights
4.1 Next-Generation Sequencing Panels
4.2 Companion Diagnostics
4.3 Immunohistochemistry Assays
4.4 Liquid Biopsy Tests
4.5 Others
Chapter 05 Application Insights
5.1 Oncology
5.2 Cardiovascular Disease
5.3 Neurology
5.4 Infectious Disease
5.5 Others
Chapter 06 End User Insights
6.1 Reference Laboratories
6.2 Hospital Laboratories
6.3 Academic Medical Centers
6.4 Pharmaceutical Companies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Labcorp
7.2.2 Quest Diagnostics
7.2.3 Natera
7.2.4 Guardant Health
7.2.5 Foundation Medicine
7.2.6 Myriad Genetics
7.2.7 Exact Sciences
7.2.8 Illumina
7.2.9 Tempus AI
7.2.10 Caris Life Sciences
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.